Findings from Linyi People's Hospital Provides New Data on Graves Disease (Iodine-131 therapy alters the immune/inflammatory responses in the thyroids of patients with Graves' disease)
By a News Reporter-Staff News Editor at Health & Medicine Week Data detailed on Autoimmune Diseases and Conditions - Graves Disease have been presented. According to news reporting from Shandong, People's Republic of China, by NewsRx journalists, research stated, "The aim of the present study was to evaluate the serum levels of interleukin-6 (IL-6), CXC chemokine ligand-10 (CXCL-10) and intercellular adhesion molecule-l (ICAM-1) in patients with Graves' disease (GD) following iodine-131 (I) therapy. A total of 30 patients with GD participated in the present study."
The news correspondents obtained a quote from the research from Linyi People's Hospital, "Serum cytokine levels were measured with ELISA, and correlation analyses were performed. Serum levels of IL-6, CXCL-10 and ICAM-1 were significantly higher in patients with GD prior to treatment than those in the control subjects (p <0.01). Following I therapy, the serum levels of IL-6 and CXCL-10 in patients with GD were markedly increased within the first week, gradually decreased to the pretreatment level in the subsequent six months and decreased further at 18 months post-treatment. However, the serum levels of IL-6 and CXCL-10 in patients with GD at 18 months following I therapy remained significantly higher than in control subjects (p <0.01). Conversely, serum ICAM-1 levels in patients with GD were gradually increased in the 12 months following I therapy and reached a relatively stable level thereafter. Furthermore, the Pearson's correlation analysis indicated that the serum levels of IL-6, CXCL-10 and ICAM-1 were not associated with free triiodothyronine, the free thyroxine index, and thyroid-stimulating hormone in these patients. I therapy was able to alter the immune/inflammatory responses in the thyroids of patients with GD."
According to the news reporters, the research concluded: "However, these cytokines (IL-6, CXCL-10, and ICAM-1) are not associated with thyroid function; therefore, they cannot be used as prognostic markers for the I therapy of GD."
For more information on this research see: Iodine-131 therapy alters the immune/inflammatory responses in the thyroids of patients with Graves' disease. Experimental and Therapeutic Medicine, 2017;13(3):1155-1159 (see also Autoimmune Diseases and Conditions - Graves Disease).
Our news journalists report that additional information may be obtained by contacting W. Du, Dept. of Endocrinology, Linyi People's Hospital, Linyi, Shandong 276000, People's Republic of China. Additional authors for this research include Q. Dong, X. Lu, X. Liu, Y. Wang, W. Li, Z. Pan, Q. Gong, C. Liang and G. Gao.
Keywords for this news article include: Asia, Iodine, Goiters, Therapy, Shandong, Halogens, Exophthalmos, Endocrinology, Graves Disease, Hyperthyroidism, People's Republic of China, Orbital Diseases and Conditions, Thyroid Diseases and Conditions, Autoimmune Diseases and Conditions, Immune System Diseases and Conditions.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC